Pursuant to Regulation 10(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, Evonile Pharma has submitted the revised Integrated Filing (Financial) for the quarter and half year ended September 30, 2026, comprising the Unaudited Financial Statements together with the Limited Review Report thereon (Annexures I and II) and other disclosures forming part of the said filing. This revised filing is being submitted solely to rectify an inadvertent omission in the heading of the table appearing under ‘Disclosure of Outstanding Default on Loans and Debt Securities’ on page 2 of the disclosure submitted earlier on November 03, 2026, at 7:23 p.m. While the figures disclosed in the table were correctly stated, the expression ‘(INR in crores)’ was inadvertently omitted from the column heading. Accordingly, it has clarified that the amount disclosed against ‘A. Total amount outstanding as on date’ under ‘Loans/Revolving Facilities like Cash Credit from Banks/Financial Institutions’ should be read as ?800 crores as on September 30, 2026. Further, the amount disclosed against ‘Total financial indebtedness of the listed entity including short-term and long-term debt’ should also be read as ?800 crores. The company has confirmed that all other disclosures and particulars contained in the earlier submission remain unchanged. There is no change whatsoever in the Unaudited Financial Results, Limited Review Report, Related Party Transactions disclosure, or any other information forming part of the Integrated Filing (Financial). This revised filing is being made solely to correct the aforesaid omission in the table heading.
The above information is a part of company’s filings submitted to BSE.
